Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Life Sciences, Medical Devices & Health Information Technology
2025: Top 10 U.S. Biopharma Clusters 2025
Massachusetts
*Industry: Massachusetts
Invivyd, Inc. (NASDAQ: IVVD), formerly, Adagio Therapeutics, Inc. (NASDAQ: ADGI)*

Organization & Developments: Invivyd

Parents

Invivyd, Inc. (NASDAQ: IVVD), formerly, Adagio Therapeutics, Inc. (NASDAQ: ADGI)*

*The company is developing its lead prospect, ADG20, for the prevention of COVID-19 infection as well as for the treatment of patients who have fallen ill. It may be zeroing in on SARS-CoV-2—the virus that causes COVID-19—but ADG20 and Adagio’s other antibodies are designed to protect against other coronaviruses, too.
*They bind to a piece of the spike protein that is found on multiple viruses, including SARS-CoV-1 and some coronaviruses circulating in bats.
2020: Adagio, 'firing on all cylinders,' grabs $80M for COVID-19 antibody
2022: Adagio adopts new name, adds Covid cocktail candidate in ‘new day’ bid after initial drug development woes
2025: Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
2025: Invivyd rallies amid interest in COVID therapy
2025: Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions
2026: Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate - Slideshow